Résultats de la recherche

search

Rechercher les filtres

Organisation
Bio-Path Holdings, Inc.
Bio-Path Logo.jpg
Bio-Path Holdings Expands Global Patent Portfolio
13 févr. 2025 16h01 HE | Bio-Path Holdings, Inc.
HOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Logo.jpg
Bio-Path Holdings Provides Key Clinical Updates
13 févr. 2025 08h00 HE | Bio-Path Holdings, Inc.
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase...
Bio-Path Logo.jpg
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
12 févr. 2025 16h01 HE | Bio-Path Holdings, Inc.
Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12,...
Bio-Path Logo.jpg
Bio-Path Holdings Provides 2025 Clinical and Operational Update
10 janv. 2025 07h00 HE | Bio-Path Holdings, Inc.
Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path...
Bio-Path Logo.jpg
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
19 déc. 2024 07h00 HE | Bio-Path Holdings, Inc.
HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Logo.jpg
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
11 déc. 2024 07h00 HE | Bio-Path Holdings, Inc.
Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic Program and Discontinues Enrollment...
Bio-Path Logo.jpg
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
15 nov. 2024 07h00 HE | Bio-Path Holdings, Inc.
Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a...
Bio-Path Logo.jpg
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
08 nov. 2024 07h00 HE | Bio-Path Holdings, Inc.
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Logo.jpg
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
10 oct. 2024 17h24 HE | Bio-Path Holdings, Inc.
HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and...
Bio-Path Logo.jpg
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
08 oct. 2024 20h00 HE | Bio-Path Holdings, Inc.
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and...